Microsatellite Instability Predicts Poor Short-Term Survival in Patients with Advanced Breast Cancer after High-Dose Chemotherapy and Autologous Stem-Cell Transplantation

Clinical Cancer Research

Volumn 10, Issue 2, 2004, Pages 556-564

  Wild, Peter J ^a   Reichle, Albrecht ^a   Andreesen, Reinhard ^a   Röckelein, Georg ^b   Dietmaier, Wolfgang ^a   Rüschoff, Josef ^c   Blaszyk, Hagen ^d   Hofstädter, Ferdinand ^a   Hartmann, Arndt ^a,e  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Institute of Pathology and Anatomy   (Germany)

^c KLINIKUM KASSEL   (Germany)

^d UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; EPIRUBICIN; ETOPOSIDE; IFOSFAMIDE; MOLECULAR MARKER; NUCLEOTIDE; PROTEIN MLH1; PROTEIN MSH2; TETRANUCLEOTIDE; UNCLASSIFIED DRUG; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE E;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG MEGADOSE; DRUG RESISTANCE; DRUG RESPONSE; FEMALE; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LASER MICRODISSECTION; LYMPH NODE METASTASIS; MENOPAUSE; MICROSATELLITE INSTABILITY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; RISK FACTOR; SEQUENCE ANALYSIS; TUMOR SUPPRESSOR GENE;

ADULT; BREAST NEOPLASMS; EXONS; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MENOPAUSE; MICROSATELLITE REPEATS; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTOR, ERBB-2; STEM CELL TRANSPLANTATION; TIME FACTORS; TREATMENT OUTCOME;

EID: 0842268390     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-0601-03     Document Type: Article

References (46)

1. Peters, W. P., Rosner, G., Vredenburgh, J., Shpall, E. J., Crump, M., Marks, L., Cirrincione, C., Hurd, D., and Norton, L. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents (AA) as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes (LN): CALGB 9082/SWOG 9114/NCIC Ma-13. Proc. Am. Soc. Clin. Oncol., 20: 21a, 2001.
2. Isaacs, C., Stearns, V., and Hayes, D. F. New prognostic factors for breast cancer recurrence. Semin. Oncol., 28: 53-67, 2001.
3. Possinger, K., Wagner, H., Langecker, P., and Wilmanns, W. Treatment toxicity reduction: breast cancer. Cancer Treat. Rev., 14: 263-274, 1987.
4. Sobin, L. H., and Wittekind, C. H. (eds.). TNM Classification of Malignant Tumors. New York, NY: Wiley-Liss, Inc., 2002.
5. Rosen, P. P., and Oberman, H. A. Tumors of the mammary gland. In: J. Rosai and L. H. Sobin (eds.), Atlas of Tumor Pathology, fasc. 7. Washington, DC: Armed Forces Institute of Pathology, 1992.
6. Wild. P., Knuechel, R., Dietmaier, W., Hofstaedter, F., and Hartmann, A. Laser microdissection and microsatellite analyses of breast cancer reveal a high degree of tumor heterogeneity. Pathobiology, 68: 180-190, 2000.
7. Kovach, J. S., McGovern, R. M., Cassady, J. D., Swanson, S. K., Wold, L. E., Vogelstein, B., and Sommer, S. S. Direct sequencing from touch preparations of human carcinomas: analysis of p53 mutations in breast carcinomas. J. Natl. Cancer Inst. (Bethesda), 83: 1004-1009, 1991.
8. Dietmaier, W., Hartmann, A., Wallinger, S., Heinmoller, E., Kerner, T., Endl, E., Jauch, K. W., Hofstadter, F., and Ruschoff, J. Multiple mutation analyses in single tumor cells with improved whole genome amplification. Am. J. Pathol., 154: 83-95, 1999.
9. Hartmann, A., Rosner, U., Schlake, G., Dietmaier, W., Zaak, D., Hofstaedter, F., and Knuechel, R. Clonality and genetic divergence in multifocal low-grade superficial urothelial carcinoma as determined by chromosome 9 and p53 deletion analysis. Lab. Investig., 80: 709-718, 2000.
10. Schlegel, J., Bocker, T., Zirngibl, H., Hofstadter, F., and Ruschoff, J. Detection of microsatellite instability in human colorectal carcinomas using a non-radioactive PCR-based screening technique. Virchows Arch., 426: 223-227, 1995.
11. Boland, C. R., Thibodeau, S. N., Hamilton, S. R., Sidransky, D., Eshleman, J. R., Burt, R. W., Meltzer, S. J., Rodriguez-Bigas, M. A., Fodde, R., Ranzani, G. N., and Srivastava, S. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res., 58: 5248-5257, 1998.
12. Hartmann, A., Schlake, G., Zaak, D., Hungerhuber, E., Hofstetter, A., Hofstaedter, F., and Knuechel, R. Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. Cancer Res., 62: 809-818, 2002.
13. Dietmaier, W., Wallinger, S., Bocker, T., Kullmann, F., Fishel, R., and Ruschoff, J. Diagnostic microsatellite instability: definition and correlation with mismatch repair protein expression. Cancer Res., 57: 4749-4756, 1997.
14. Graziano, C. HER-2 breast assay, linked to Herceptin, wins FDA's okay. CAP Today, 12: 1, 14-16, 1998.
15. Kaplan, E. L., and Meier, P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc., 53: 457-481, 1958.
16. Peto, R., and Peto, J. Regression models and life tables. J. R. Stat. Soc. B, 135: 185-188, 1972.
17. Cox, D. R. Regression models and life tables. J. R. Stat. Soc. B, 34: 187-220, 1972.
18. Lengauer, C., Kinzler, K. W., and Vogelstein, B. Genetic instability in colorectal cancers. Nature (Lond.), 386: 623-627, 1997.
19. Hartmann, A., Blaszyk, H., McGovern, R. M., Schroeder, J. J., Cunningham, J., De Vries, E. M., Kovach, J. S., and Sommer, S. S. p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers. Oncogene, 10: 681-688, 1995.
20. Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J., Schaid, D., and Sommer, S. S. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci. USA, 93: 1093-1096, 1996.
21. Siah, S. P., Quinn, D. M., Bennett, G. D., Casey, G., Flower, R. L., Suthers, G., and Rudzki, Z. Microsatellite instability markers in breast cancer: a review and study showing MSI was not detected at 'BAT 25' and 'BAT 26' microsatellite markers in early-onset breast cancer. Breast Cancer Res. Treat., 60: 135-142, 2000.
22. Anbazhagan, R., Fujii, H., and Gabrielson, E. Microsatellite instability is uncommon in breast cancer. Clin. Cancer Res., 5: 839-844, 1999.
23. Risinger, J. I., Barrett, J. C., Watson, P., Lynch, H. T., and Boyd, J. Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. Cancer (Phila.), 77: 1836-1843, 1996.
24. Lothe, R. A., Peltomaki, P., Meling, G. I., Aaltonen, L. A., Nystrom-Lahti, M., Pylkkanen, L., Heimdal, K., Andersen, T. I., Moller, P., and Rognum, T. O. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res., 53: 5849-5852, 1993.
25. Muller, A., and Fishel, R. Mismatch repair and the hereditary non-polyposis colorectal cancer syndrome (HNPCC). Cancer Investig., 20: 102-109, 2002.
26. Gryfe, R., Kim, H., Hsieh, E. T., Aronson, M. D., Holowaty, E. J., Bull, S. B., Redston, M., and Gallinger, S. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med., 342: 69-77, 2000.
27. Ribic, C. M., Sargent, D. J., Moore, M. J., Thibodeau, S. N., French, A. J., Goldberg, R. M., Hamilton, S. R., Laurent-Puig, P., Gryfe, R., Shepherd, L. E., Tu, D., Redston, M., and Gallinger, S. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med., 349: 247-257, 2003.
28. Zekri, A. R., Bahnassi, A. A., Bove, B., Huang, Y., Russo, I. H., Rogatko, A., Shaarawy, S., Shawki, O. A., Hamza, M. R., Omer, S., Khaled, H. M., and Russo, J. Allelic instability as a predictor of survival in Egyptian breast cancer patients. Int. J. Oncol., 15: 757-767, 1999.
29. De Marchis, L., Contegiacomo, A., D'Amico, C., Palmirotta, R., Pizzi, C., Ottini, L., Mastranzo, P., Figliolini, M., Petrella, G., Amanti, C., Battista, P., Bianco, A. R., Frati, L., Cama, A., and Mariani-Costantini, R. Microsatellite instability is correlated with lymph node-positive breast cancer. Clin. Cancer Res., 3: 241-248, 1997.
30. Paulson, T. G., Wright, F. A., Parker, B. A., Russack, V., and Wahl, G. M. Microsatellite instability correlates with reduced survival and poor disease prognosis in breast cancer. Cancer Res., 56: 4021-4026, 1996.
31. Tomita, S., Deguchi, S., Miyaguni, T., Muto, Y., Tamamoto, T., and Toda, T. Analyses of microsatellite instability and the transforming grbwth factor-β receptor type II gene mutation in sporadic breast cancer and their correlation with clinicopathological features. Breast Cancer Res. Treat., 53: 33-39, 1999.
32. Muller, A., Edmonston, T. B., Corao, D. A., Rose, D. G., Palazzo, J.P., Becker, H., Fry, R. D., Rueschoff, J., and Fishel, R. Exclusion of breast cancer as an integral tumor of hereditary nonpolyposis colorectal cancer. Cancer Res., 62: 1014-1019, 2002.
33. Rosenberg, C. L., de las, M., Huang, K., Cupples, L. A., Faller, D. V., and Larson, P. S. Detection of monoclonal microsatellite alterations in atypical breast hyperplasia. J. Clin. Investig., 98: 1095-1100, 1996.
34. Aldaz, C. M., Chen, T., Sahin, A., Cunningham, J., and Bondy, M. Comparative allelotype of in situ and invasive human breast cancer: high frequency of microsatellite instability in lobular breast carcinomas. Cancer Res., 55: 3976-3981, 1995.
35. Ahrendt, S. A., Decker, P. A., Doffek, K., Wang, B., Xu, L., Demeure, M. J., Jen, J., and Sidransky, D. Microsatellite instability at selected tetranucleotide repeats is associated with p53 mutations in non-small cell lung cancer. Cancer Res., 60: 2488-2491, 2000.
36. Schrama, J. G., Faneyte, I. F., Schornagel, J. H., Baars, J. W., Peterse, J. L., van, d. V., Dalesio, O., van Tinteren, H., Rutgers, E. J., Richelt, D. J., and Rodenhuis, S. Randomized trial of high-dose-chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann. Oncol., 13: 689-698, 2002.
37. Climent, J., Martinez-Climent, J. A., Blesa, D., Garcia-Barchino, M. J., Saez, R., Sanchez-Izquierdo, D., Azagra, P., Lluch, A., and Garcia-Conde, J. Genomic loss of 18p predicts an adverse clinical outcome in patients with high-risk breast cancer. Clin. Cancer Res., 8: 3863-3869, 2002.
38. Bertheau, P., Plassa, F., Espie, M., Turpin, E., de Roquancourt, A., Marty, M., Lerebours, F., Beuzard, Y., Janin, A., and de The, H. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet, 360: 852-854, 2002.
39. Bergh, J., Norberg, T., Sjogren, S., Lindgren, A., and Holmberg, L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat. Med., 1: 1029-1034, 1995.
40. Berns, E. M., Foekens, J. A., Vossen, R., Look, M. P., Devilee, P., Henzen-Logmans, S. C., van, S. I., van Putten, W. L., Inganas, M., Meijer-van Gelder, M. E., Cornelisse, C., Claassen, C. J., Portengen, H., Bakker, B., and Klijn, J. G. Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer. Cancer Res., 60: 2155-2162, 2000.
41. Hensel, M., Schneeweiss, A., Sinn, H. P., Egerer, G., Solomayer, E., Haas, R., Bastert, G., and Ho, A. D. P53 is the strongest predictor of survival in high-risk primary breast cancer patients undergoing high-dose chemotherapy with autologous blood stem cell support. Int. J. Cancer, 100: 290-296, 2002.
42. Hartmann, A., Blaszyk, H., Kovach, J. S., and Sommer, S. S. The molecular epidemiology of p53 gene mutations in human breast cancer. Trends Genet., 13: 27-33, 1997.
43. Makris, A., Powles, T. J., Dowsett, M., and Allred, C. p53 protein overexpression and chemosensitivity in breast cancer. Lancet, 345: 1181-1182, 1995.
44. Kim, Y. S., Konoplev, S. N., Montemurro, F., Hoy, E., Smith, T. L., Rondon, G., Champlin, R. E., Sahin, A. A., and Ueno, N. T. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin. Cancer Res., 7: 4008-4012, 2001.
45. Nieto, Y., Cagnoni, P. J., Nawaz, S., Shpall, E. J., Yerushalmi, R., Cook, B., Russell, P., McDermit, J., Murphy, J., Bearman, S. I., and Jones, R. B. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. J. Clin. Oncol., 18: 2070-2080, 2000.
46. Nieto, Y., Nawaz, S., Jones, R. B., Shpall, E. J., Cagnoni, P. J., McSweeney, P. A., Baron, A., Razook, C., Matthes, S., and Bearman, S. I. Prognostic model for relapse after high-dose chemotherapy with autologous stem-cell transplantation for stage IV oligometastatic breast cancer. J. Clin. Oncol., 20: 707-718, 2002.